Analysis and Prediction Study on the Burden of Drug Use Disorders in China from 1990 to 2023: A Systematic Analysis From the Global Burden of Disease Study 2023.
{"title":"Analysis and Prediction Study on the Burden of Drug Use Disorders in China from 1990 to 2023: A Systematic Analysis From the Global Burden of Disease Study 2023.","authors":"Enda Xia, Gang Chen, Jinjuan Duan","doi":"10.1080/10826084.2026.2716890","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction: </strong>Drug use disorders, including amphetamine use disorder (AMD), cocaine use disorder (COD), cannabis use disorder (CAD), opioid use disorder (OPD), and other drug use disorder (OTD), have become a serious global public health issue. However, there are limited systematic reviews and studies on drug use disorders in China.</p><p><strong>Methods: </strong>The Joinpoint regression method was used to comprehensively evaluate the changes in the burden of drug use disorders in China from 1990 to 2023. The systematic analysis was conducted by stratifying by gender and age group, and the future burden of drug use disorders in China was predicted based on the difference autoregressive moving average model (ARIMA).</p><p><strong>Results: </strong>In 2023, the prevalence of AMD, COD, CAD, OPD, and OTD were 218.45, 162.13, 4.22, 109.27, and 21.31 per 100,000 in China, respectively. From 1990 to 2023, the burden of AMD, COD, OPD, and OTD in China all showed a downward trend, while the burden of CAD remained relatively stable. Additionally, from 1990 to 2023, the burden of AMD, COD, and CAD among Chinese males was significantly higher than that among females, while the gender differences in the burden of OPD and OTD varied in different periods. In terms of age stratification, the disease burden of different drug use disorders varies significantly among different age groups. Moreover, the prevalence and DALYs rate of drug use disorders decreased with increasing age. However, it is necessary to be vigilant that the proportions of OPD and AMD are constantly increasing among the elderly. The prediction results indicate that in the next 15 years, the disease burden of AMD, COD, OPD, and OTD in China will further decrease, while the disease burden of CAD will remain relatively stable.</p><p><strong>Conclusions: </strong>The disease burden of drug use disorders in China remains significant, and there are notable differences among different genders and age groups. In the future, more targeted prevention measures should be developed based on the current situation and the characteristics of gender and age stratification, in order to effectively reduce the disease burden of corresponding drug use disorders.</p>","PeriodicalId":22088,"journal":{"name":"Substance Use & Misuse","volume":" ","pages":"1-9"},"PeriodicalIF":1.7000,"publicationDate":"2026-08-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Substance Use & Misuse","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/10826084.2026.2716890","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"PSYCHIATRY","Score":null,"Total":0}
引用次数: 0
Abstract
Introduction: Drug use disorders, including amphetamine use disorder (AMD), cocaine use disorder (COD), cannabis use disorder (CAD), opioid use disorder (OPD), and other drug use disorder (OTD), have become a serious global public health issue. However, there are limited systematic reviews and studies on drug use disorders in China.
Methods: The Joinpoint regression method was used to comprehensively evaluate the changes in the burden of drug use disorders in China from 1990 to 2023. The systematic analysis was conducted by stratifying by gender and age group, and the future burden of drug use disorders in China was predicted based on the difference autoregressive moving average model (ARIMA).
Results: In 2023, the prevalence of AMD, COD, CAD, OPD, and OTD were 218.45, 162.13, 4.22, 109.27, and 21.31 per 100,000 in China, respectively. From 1990 to 2023, the burden of AMD, COD, OPD, and OTD in China all showed a downward trend, while the burden of CAD remained relatively stable. Additionally, from 1990 to 2023, the burden of AMD, COD, and CAD among Chinese males was significantly higher than that among females, while the gender differences in the burden of OPD and OTD varied in different periods. In terms of age stratification, the disease burden of different drug use disorders varies significantly among different age groups. Moreover, the prevalence and DALYs rate of drug use disorders decreased with increasing age. However, it is necessary to be vigilant that the proportions of OPD and AMD are constantly increasing among the elderly. The prediction results indicate that in the next 15 years, the disease burden of AMD, COD, OPD, and OTD in China will further decrease, while the disease burden of CAD will remain relatively stable.
Conclusions: The disease burden of drug use disorders in China remains significant, and there are notable differences among different genders and age groups. In the future, more targeted prevention measures should be developed based on the current situation and the characteristics of gender and age stratification, in order to effectively reduce the disease burden of corresponding drug use disorders.
期刊介绍:
For over 50 years, Substance Use & Misuse (formerly The International Journal of the Addictions) has provided a unique international multidisciplinary venue for the exchange of original research, theories, policy analyses, and unresolved issues concerning substance use and misuse (licit and illicit drugs, alcohol, nicotine, and eating disorders). Guest editors for special issues devoted to single topics of current concern are invited.
Topics covered include:
Clinical trials and clinical research (treatment and prevention of substance misuse and related infectious diseases)
Epidemiology of substance misuse and related infectious diseases
Social pharmacology
Meta-analyses and systematic reviews
Translation of scientific findings to real world clinical and other settings
Adolescent and student-focused research
State of the art quantitative and qualitative research
Policy analyses
Negative results and intervention failures that are instructive
Validity studies of instruments, scales, and tests that are generalizable
Critiques and essays on unresolved issues
Authors can choose to publish gold open access in this journal.